JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Simulations Plus Inc

Cerrado

SectorSanidad

14.28 -5.62

Resumen

Variación precio

24h

Actual

Mínimo

14.03

Máximo

15.13

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+5.33% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.24%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

51M

302M

Apertura anterior

19.9

Cierre anterior

14.28

Noticias sobre sentimiento de mercado

By Acuity

6%

94%

4 / 348 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 abr 2026, 00:00 UTC

Ganancias

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 abr 2026, 23:47 UTC

Charlas de Mercado

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 abr 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 abr 2026, 23:13 UTC

Adquisiciones, fusiones, absorciones

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 abr 2026, 22:33 UTC

Ganancias

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 abr 2026, 22:17 UTC

Ganancias

PLS Executed Offtake Agreement With Ronbay

23 abr 2026, 22:17 UTC

Ganancias

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 abr 2026, 22:16 UTC

Ganancias

PLS Commences Commissioning of Midstream Demonstration Plant

23 abr 2026, 22:15 UTC

Ganancias

PLS Group Reaffirms FY26 Guidance for All Metrics

23 abr 2026, 22:14 UTC

Ganancias

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 abr 2026, 22:14 UTC

Ganancias

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 abr 2026, 22:13 UTC

Ganancias

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 abr 2026, 22:12 UTC

Ganancias

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 abr 2026, 22:12 UTC

Ganancias

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 abr 2026, 22:11 UTC

Ganancias

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 abr 2026, 22:10 UTC

Ganancias

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 abr 2026, 22:09 UTC

Ganancias

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 abr 2026, 22:08 UTC

Ganancias

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 abr 2026, 22:04 UTC

Ganancias

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 abr 2026, 21:56 UTC

Charlas de Mercado
Ganancias

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 abr 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 abr 2026, 21:27 UTC

Ganancias

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 abr 2026, 21:25 UTC

Ganancias

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 abr 2026, 21:24 UTC

Ganancias

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 abr 2026, 21:24 UTC

Ganancias

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 abr 2026, 21:21 UTC

Ganancias

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 abr 2026, 21:21 UTC

Ganancias

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

5.33% repunte

Estimación a 12 Meses

Media 16 USD  5.33%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

4 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat